Cardiovascular safety trial demonstrating that the DPP-4 inhibitor alogliptin does not increase MACE in patients with T2DM who had a recent acute coronary event
With a 6-day half-life, more frequent smaller doses accumulate toward nearly the same ceiling holding the weekly total constant, the steady-state peak falls only about 19% on q3d and about 17% on q3.5d, not the 57% the swing figure might suggest
Follow instructions from your own clinician
Even if you are in Colorado or California where recreational pot is legal, as a service member you are still subject to federal law and UCMJ
Years of post-marketing data, cardiovascular outcome trials showing actual event reduction, kidney benefits, and extensive real-world experience provide a level of certainty that retatrutide simply cannot match yet
Your doctor mentioned it might be something to watch, a buddy on a forum said you need to donate blood yesterday, and you're wondering if te